Article: Long-term benefit of acalabrutinib in first-line CLL: 6-year update from ELEVATE-TN

€3.03

SKU: product-article-44226 Category: General

Description

Description

Long-term benefit of acalabrutinib in first-line CLL: 6-year update from ELEVATE-TN

Top

Article: Long-term benefit of acalabrutinib in first-line CLL: 6-year update from ELEVATE-TN

Description

Related products

Article: Highlights in respiratory oncology

Article: Highlights in breast cancer

Article: Highlights in squamous cell carcinoma of the head and neck

1 year subscription print edition of the Belgian Journal of Hematology (BJH)